Abstract: Methods and compositions are provided comprising acriflavine for inhibiting and treating diseases and disorders associated with pathogenic proteins causing neurodegenerative diseases and amyloid diseases, such as protease resistant prion proteins (PrPSc) and those associated with transmissible spongiform encephalopathies (TSEs), Alzheimer's disease, amyloidosis, and the like.

Abstract: Novel carbaphens are provided of the formula ##STR1## wherein R is OH, OCON(CH.sub.3).sub.2 or OCONHCH.sub.3, and R' is H, OH or sub.2 OCON(CH.sub.3).sub.2, stereoisomers thereof, pharmaceutically-acceptable salts thereof or mixtures thereof.Compositions comprise the carbaphens with pharmaceutically acceptable carriers, and they may further comprise other drugs as well.Methods of treating patients either prophylactically or therapeutically which suffer from organophosphate poisoning, coronary insufficiency, cerebral vasospasms, spastic cholitis and cholecystitis comprise the administration of the carbaphens of the invention.

Abstract: Novel carbaphens are provided of the formula ##STR1## wherein R is OH, OCON(CH.sub.3).sub.2 or OCONHCH.sub.3, and R' is H, OH or .sub.2 OCON(CH.sub.3).sub.2, stereoisomers thereof, pharmaceutically-acceptable salts thereof or mixtures thereof.Compositions comprise the carbaphens with pharmaceutically acceptable carriers, and they may further comprise other drugs as well.Methods of treating patients either prophylactically or therapeutically which suffer from organophosphate poisoning, coronary insufficiency, cerebral vasospasms, spastic cholitis and cholecystitis comprise the administration of the carbaphens of the invention.

Abstract: This invention relates to novel compositions, their preparation and the use thereof as anticholinergic agents in the treatment or prophylaxis of organophosphate or nerve gas poisoning in animals. These compositions and pharmaceutical preparations containing them in their free base form and acid addition salts thereof are represented by the formula ##STR1## wherein R represents lower alkyl groups containing 1 to 7 carbon atoms; R.sup.1 represents hydrogen, phenyl, cyclohexyl, and cyclopentyl; and R.sup.2 represents lower alkyl groups containing 1 to 7 carbon atoms, hydroxymethyl, and hydroxyl.

Abstract: (.+-.)3-Deazaaristeromycin, also known as (.+-.)-4-amino-1-[(1.alpha., 2.beta., 3.beta., 4.alpha.)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl]imidazo[4,5-c]pyridin e, utilized as a novel antiviral agent and inhibiting S-adenosylhomocysteine hydrolase in a pharmacological target in effective concentrations.

Abstract: 5'-Deoxy-5'-(isobutylthio)-3-deazaadenosine and a method for preparation of same. In the preparation, 3-deazaadenosine is utilized as a starting material and is chlorinated at the 5' position. Subsequently, the chloro group is converted to isobutylthio by reaction with isobutyl mercaptan in ethanol containing sodium methoxide giving the desired compound.A most preferred starting material, i.e., 3-deazaadenosine, was prepared according to the method of Montgomery et al, J. Heterocyclic Chem., 14:195 (1977). The key fusion of this process is 4,6-dichloroimidazo[4,5-c]pyridine with 1,2,3,5-tetra-O-acetyl-.beta.-D-ribofuranose, which, after removal of protective groups and reductive dechlorination of the chlorine at 6, gives 3-deazaadenosine.

Abstract: 3-Deazaadenosine has been found to be an effective antiviral and antifocal agent in tissue culture of animals as evidenced by its activity against Rous sarcoma virus, influenza virus, vesicular stomatitis virus, Sindbis virus, and Newcastle disease virus in the range 0.03-0.3 mM. This compound has also shown use as an inhibitor of adenosylhomocysteine hydrolase from beef liver in the range of 0.001-0.008 mM (I.sub.50). The antiviral and antifocal effect is correlated with the inhibition of hydrolysis of adenosylhomocysteine in cells. This inhibition of adenosylhomocysteine hydrolase can also be demonstrated in livers of rats injected with 3-deazaadenosine.